Skip to main content
. 2019 Feb 13;10(Suppl 1):1–13. doi: 10.1007/s13300-019-0573-y

Fig. 3.

Fig. 3

Percent of real world patients eligible for Diabetes RCTs

Adapted with permission from: Saunders, C., C.D. Byrne, B. Guthrie, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30:300–8. [56] and McGovern, A., M. Feher, N. Munro, and S. de Lusignan. Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. Diabetes Ther. 2017;8:365–76. [57]